Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Diego Tummarello"'
Autor:
Giorgio Battistuzzi, Cristina Mareni, Diego Tummarello, Gian Cesare Guidi, G. Perona, Lucio Luzzato
Publikováno v:
Scandinavian Journal of Haematology. 30:407-414
A 67-year-old woman investigated because of 'myelodysplastic syndrome' was found to have a 4-fold increase in G-6-PD activity in her erythrocytes. The enzyme was partially purified and characterized. On grounds of: (a) reduced electrophoretic mobilit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b991498bf4f04931bcf7864ca1efd806
https://doi.org/10.1111/j.1600-0609.1983.tb02526.x
https://doi.org/10.1111/j.1600-0609.1983.tb02526.x
Autor:
Pierpaolo Isidori, Diego Tummarello, Davide Mari, Gianluigi Cetto, Francesco Graziano, Antonio Santo, Felice Pasini, Riccardo Cellerino
Publikováno v:
Cancer. 80:2222-2229
BACKGROUND Studies of chemotherapy for patients with small cell lung carcinoma (SCLC) have shown that teniposide (T) may have higher activity than etoposide (E). In this randomized, controlled Phase III study, the authors compared cyclophosphamide, d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa9eefa4cf19d474df9ae8f67621d7d8
https://doi.org/10.1002/(sici)1097-0142(19971215)80:12<2222::aid-cncr2>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19971215)80:12<2222::aid-cncr2>3.0.co
Autor:
Pierpaolo Isidori, Diego Tummarello, Anna Fedeli, Antonio Santo, Francesco Graziano, Gianluigi Cetto, Riccardo Cellerino, Giorgio Rossi
Publikováno v:
Cancer. 77:2251-2257
BACKGROUND The authors investigated a consolidation biochemotherapy program with subcutaneous recombinant interleukin-2 (rIL-2) and recombinant interferon-α (rIFNα) biologic response modifiers (BRM) in patients with advanced nonsmall cell lung carc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0641f866a13c2892420c835e30b994c0
https://doi.org/10.1002/(sici)1097-0142(19960601)77:11<2251::aid-cncr11>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19960601)77:11<2251::aid-cncr11>3.0.co
Publikováno v:
Cancer Chemotherapy and Pharmacology. 35:249-253
In a series of 46 symptomatic patients with metastatic, stage IV, non-small-cell lung cancer (NSCLC), we used a three-drug combination with cisplatin (120 mg/m2), vinblastine (6 mg/m2) and mitomycin-C (6 mg/m2) (PVM), repeated every 3 weeks. After tw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::028c556f0c9bede2692d3ddbf7cba4f8
https://doi.org/10.1007/bf00686556
https://doi.org/10.1007/bf00686556
Publikováno v:
European Journal of Cancer. 28:1081-1084
From January 1987 to December 1990, 26 105 previously untreated patients affected by small cell lung cancer (SCLC), not suitable for intensive SCLC treatment since 19 of them were older than 70 years and 7 suffered from severe chronic diseases, recei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ddfa8f8cfd7839a093226c67955044f
https://doi.org/10.1016/0959-8049(92)90462-b
https://doi.org/10.1016/0959-8049(92)90462-b
Autor:
Biscottini B, P. Isidori, Diego Tummarello, Riccardo Cellerino, Raspugli M, Guidi F, Giuseppe Fatati
Publikováno v:
Journal of Clinical Oncology. 9:1453-1461
From April 1985 to September 1988, 128 patients with advanced non-small-cell lung cancer (NSCLC) were enrolled in a prospective randomized trial evaluating chemotherapy (arm A) versus best supportive care (arm B). Chemotherapy consisted of cyclophosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::051ab5c53e4d5b33c129ce0a68750e93
https://doi.org/10.1200/jco.1991.9.8.1453
https://doi.org/10.1200/jco.1991.9.8.1453
Autor:
Riccardo Cellerino, Baldelli S, U. Torresi, B. Murer, Salvatore Miseria, Diego Tummarello, Ettore Tito Menichetti
Publikováno v:
Tumori Journal. 77:86-89
Lymphangitic carcinomatosis of the lung Is a late and often fatal manifestation of cancer. We describe a case of a biopsy-proved pulmonary lymphangitic carcinomatosis in an asymptomatic 61-year-old man. The pulmonary picture proved to be the initial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c142cf2c567720c1ae5a9b8e854fe83
https://doi.org/10.1177/030089169107700120
https://doi.org/10.1177/030089169107700120
Publikováno v:
Lung Cancer. 6:99-109
The value of chemotherapy (CT) in patients with advanced non-small cell lung cancer remains controversial. In the past 10 years results from 7 randomized studies of polychemotherapy vs best supportive care (BSC) have been published: median survival r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eedcf61b35c7b7c4c7d78f327c8dcfbd
https://doi.org/10.1016/0169-5002(90)90113-z
https://doi.org/10.1016/0169-5002(90)90113-z
Publikováno v:
Acta Oncologica. 29:417-420
Seventy-four patients with small cell lung cancer (SCLC) entered a program consisting of induction with three courses of CAV (cyclophosphamide, doxorubicin and vincristine) in limited disease or two courses of CAV plus two courses of DDP-VP16 (cispla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::753dbefb1208438b7320cc996006149d
https://doi.org/10.3109/02841869009090023
https://doi.org/10.3109/02841869009090023
Autor:
Cristian Massacesi, Angelo Dinota, Francesca Giorgi, Luigi Manzione, Diego Tummarello, Chiara Braconi, Nicola Battelli, Stefano Cascinu, Donatella Morale, Fabio Sturba, Alberto Scanni, Giusi Giacomini, Stefano Cobelli, Alberta Pilone
Publikováno v:
American journal of clinical oncology. 29(4)
Objective: The aim of this study was to evaluate the feasibility of a combination of epirubicin and paclitaxel followed by intravenous (iv) cyclophosphamide, methotrexate, and 5-fluorouracile (CMF) as adjuvant treatment of breast cancer patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d2db21b6899e50ba5af50faeac9d30c
https://pubmed.ncbi.nlm.nih.gov/16891866
https://pubmed.ncbi.nlm.nih.gov/16891866